Kingdomway(SZ:002626)2026-01-28 01:55Key Points Summary Company and Industry Involved - The report focuses on the company "金达威" (Jindawi) and its operations in the dietary supplement industry, particularly in the production of coenzyme Q10 and contract manufacturing for brands like 多特倍斯 (Duotebei) and others [1][2]. Core Insights and Arguments 1. Coenzyme Q10 Pricing: The current price of coenzyme Q10 is considered reasonable, with a decrease noted in December followed by a recovery in January and February due to strong demand. The expectation for 2026 is an increase in volume but a decrease in price, with a target gross margin of 45%-50% [1][1]. 2. Contract Manufacturing (VB): - Anticipated acceleration in revenue from the VB segment, which currently only produces tablets and hard capsules, with soft capsule production expected to start in April [1][1]. - The VB manufacturing process and delivery timelines have been clarified, indicating self-sustaining capabilities that allow participation in large project tenders. Orders have been received from clients like Duotebei, Walmart, and iHerb, although the current volume is small [1][1]. 3. Brand Strategy: - Duotebei in the U.S. aims for modest growth, influenced by consumer trends. In China, the focus for 2025 will be on return on investment, with significant investments planned for 2026 to enhance brand penetration and volume, while relaxing profit expectations [1][1]. 4. Cross-Border Product Management: The company is leveraging its advantages in cross-border product management, particularly through platforms like Douyin [2][1]. 5. Investment in U.S. Contract Manufacturing: Increased investment in U.S. contract manufacturing is highlighted, showcasing a strong competitive edge across the entire supply chain, despite lower margins downstream [2][1]. Other Important but Potentially Overlooked Content 1. Change in Fund Utilization: - Plans to establish a smart factory focusing on proprietary health products, potentially utilizing the existing brand "金乐心" (Jinlexin), targeting affordable products in lower-tier cities, specifically in coenzyme Q10 and PQQ [3][1]. - A new project focusing on algae oil, particularly EPA, aimed at vascular health, is also mentioned [3][1]. 2. Market Dynamics: The report notes that Douyin's special governance on cross-border VDS is expected to improve competitive dynamics in 2026, alongside increased domestic investments by Duotebei [3][1]. 3. Empowerment through Smart Factory: The smart factory in Inner Mongolia is positioned to empower the consumer end, focusing on lower-tier markets [3][1].